• Issue

    Inflammatory Bowel Diseases: Volume 18, Issue 11

    2001-2202
    November 2012
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

In Memoriam

In Memoriam†

Stephen B. Hanauer,  David T. Rubin, 
  • Pages: 2001-2003
  • First Published: 15 October 2012

Original Clinical Articles

Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases

Sang Hyoung Park MD,  Suk-Kyun Yang MD,  Young-Suk Lim MD,  Ju Hyun Shim MD,  Dong-Hoon Yang MD,  Kee Wook Jung MD,  Kyung-Jo Kim MD,  Byong Duk Ye MD,  Jeong-Sik Byeon MD,  Seung-Jae Myung MD,  Jin-Ho Kim MD, 
  • Pages: 2004-2010
  • First Published: 15 February 2012

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents†

Pauliina Molander MD,  Clas-Göran af Björkesten MD,  Harri Mustonen DSc,  Johanna Haapamäki MD, PhD,  Matti Vauhkonen MD, PhD,  Kaija-Leena Kolho MD, PhD,  Martti Färkkilä MD, PhD,  Taina Sipponen MD, PhD, 
  • Pages: 2011-2017
  • First Published: 04 January 2012

Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control

Patrick F. van Rheenen MD, PhD, 
  • Pages: 2018-2025
  • First Published: 24 January 2012

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response† ‡

Lior Katz MD,  Javier P. Gisbert MD, PhD,  Beth Manoogian MD,  Kirk Lin MD,  Casper Steenholdt MD,  Gerassimos J. Mantzaris MD, PhD,  Ashish Atreja MD, MPH,  Yulia Ron MD,  Arun Swaminath MD,  Somal Shah MD,  Ailsa Hart PhD, MRCP,  Peter Laszlo Lakatos MD, PhD,  Pierre Ellul MD,  Eran Israeli MD,  Mads Naundrup Svendsen MD,  C. Janneke van der Woude MD, PhD,  Konstantinos H. Katsanos MD, PhD,  Laura Yun MD,  Epameinondas V. Tsianos MD, PhD,  Torben Nathan MD,  Maria Abreu MD,  Iris Dotan MD,  Bret Lashner MD, MPH,  Jorn Brynskov′ MD,  Jonathan P. Terdiman MD,  Peter D.R Higgins MD, PhD,  Maria Chaparro MD, PhD,  Shomron Ben-Horin MD, 
  • Pages: 2026-2033
  • First Published: 31 January 2012

Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis

Neal Shahidi BSc,  Yi-Tzu Nancy Fu MD,  Hong Qian MSc,  Brian Bressler MD, 
  • Pages: 2034-2042
  • First Published: 31 January 2012

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)†

Daniel A. Sussman MD, MSPH,  Nisa Kubiliun MD,  Parvez M. Mulani PhD,  Jingdong Chao PhD,  Carol A.T. Gillis PharmD,  Mei Yang PhD,  Mei Lu MS,  Maria T. Abreu MD, 
  • Pages: 2043-2055
  • First Published: 12 January 2012

Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?†

Ashwin D. Dhanda MRCP,  Tom J. Creed MD,  Rosemary Greenwood MSc,  Bruce E. Sands MD,  Christopher S. Probert MD, 
  • Pages: 2056-2062
  • First Published: 23 January 2012

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease†

Harry Sokol MD,  Laurent Beaugerie MD,  Marc Maynadié MD,  David Laharie MD,  Jean-Louis Dupas MD,  Bernard Flourié MD,  Eric Lerebours MD,  Laurent Peyrin-Biroulet MD,  Matthieu Allez MD,  Tabassome Simon MD,  Fabrice Carrat MD,  Nicole Brousse MD,  for the CESAME Study Group , 
  • Pages: 2063-2071
  • First Published: 23 January 2012

Clinical predictors at diagnosis of disabling pediatric Crohn's disease†

Guillaume Savoye MD, PhD,  Julia Salleron MS,  Corinne Gower-Rousseau MD,  Jean-Louis Dupas MD, PhD,  Gwénola Vernier-Massouille MD,  Mathurin Fumery MD,  Véronique Merle MD, PhD,  Eric Lerebours MD, PhD,  Antoine Cortot MD,  Dominique Turck MD, PhD,  Jean-Louis Salomez MD,  Marc Lemann MD,  Jean-Frédéric Colombel MD,  Alain Duhamel MD, PhD, 
  • Pages: 2072-2078
  • First Published: 31 January 2012

Pretravel preparation and travel-related morbidity in patients with inflammatory bowel disease

Darius Soonawala MD,  Anna M. van Eggermond MSc,  Herma Fidder MD, PhD,  Leo G. Visser MD, PhD, 
  • Pages: 2079-2085
  • First Published: 31 January 2012

Risk factors of anxiety and depression in inflammatory bowel disease

Stéphane Nahon MD,  Pierre Lahmek MD,  Christelle Durance,  Alain Olympie,  Bruno Lesgourgues MD,  Jean-Frédéric Colombel MD, PhD,  Jean-Pierre Gendre MD, 
  • Pages: 2086-2091
  • First Published: 31 January 2012

Barriers to enrollment in inflammatory bowel disease randomized controlled trials: An investigation of patient perspectives

Jessica E. Ravikoff MD,  Elisabeth B. Cole MS,  Joshua R. Korzenik MD, 
  • Pages: 2092-2098
  • First Published: 12 January 2012
Free Access

Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): Methodology and initial results

Millie D. Long MD, MPH,  Michael D. Kappelman MD, MPH,  Christopher F. Martin MSPH,  James D. Lewis MD, MSCE,  Lloyd Mayer MD,  Patricia M. Kinneer MA,  Robert S. Sandler MD, MPH, 
  • Pages: 2099-2106
  • First Published: 27 January 2012

Original Basic Science Articles

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates†

Eric R. Fedyk PhD,  Tim Wyant PhD,  Li-Li Yang MS,  Vilmos Csizmadia MS,  Kristine Burke MS,  Hua Yang PhD,  Vivek J. Kadambi PhD, 
  • Pages: 2107-2119
  • First Published: 14 March 2012
Open Access

Defective tumor necrosis factor release from Crohn's disease macrophages in response to toll-like receptor activation: Relationship to phenotype and genome-wide association susceptibility loci†

Gavin W. Sewell PhD,  Farooq Z. Rahman PhD,  Adam P. Levine BSc,  Luke Jostins MPhil,  Philip J. Smith MRCP,  Ann P. Walker PhD,  Stuart L. Bloom FRCP,  Anthony W. Segal PhD, FRS,  Andrew M. Smith PhD, 
  • Pages: 2120-2127
  • First Published: 20 March 2012

Mucosal genome-wide methylation changes in inflammatory bowel disease†

James Cooke PhD,  Hu Zhang PhD,  Liliana Greger PhD,  Ana-Luisa Silva PhD,  Dunecan Massey MD,  Claire Dawson MSc,  Andrew Metz MD,  Ashraf Ibrahim PhD,  Miles Parkes MD, 
  • Pages: 2128-2137
  • First Published: 14 March 2012

Multifactorial patterns of gene expression in colonic epithelial cells predict disease phenotypes in experimental colitis†

Aubrey L. Frantz BS,  Maria E.C. Bruno PhD,  Eric W. Rogier BS,  Halide Tuna BS,  Donald A. Cohen PhD,  Subbarao Bondada PhD,  R. Lakshman Chelvarajan PhD,  J. Anthony Brandon PhD,  C. Darrell Jennings MD,  Charlotte S. Kaetzel PhD, 
  • Pages: 2138-2148
  • First Published: 22 February 2012

Regulation of sodium-glutamine cotransport in villus and crypt cells by glucocorticoids during chronic enteritis

Subha Arthur PhD,  Prosenjit Saha PhD,  Shanmuga Sundaram,  Ramesh Kekuda PhD,  Uma Sundaram MD, 
  • Pages: 2149-2157
  • First Published: 16 April 2012

Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitis

Srikanth Santhanam PhD,  Subapriya Rajamanickam PhD,  Anjan Motamarry MSc,  Balakrishnan S. Ramakrishna DM, PhD,  Jayakumar G. Amirtharaj MSc,  Anup Ramachandran PhD,  Anna Pulimood MD, PhD,  Aparna Venkatraman PhD, 
  • Pages: 2158-2168
  • First Published: 28 February 2012

Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis

Satoshi Serada PhD,  Minoru Fujimoto MD, PhD,  Fumitaka Terabe MD, PhD,  Hideki Iijima MD, PhD,  Shinichiro Shinzaki MD, PhD,  Shinya Matsuzaki MD,  Tomoharu Ohkawara MD,  Riichiro Nezu MD, PhD,  Sachiko Nakajima MD, PhD,  Taku Kobayashi MD, PhD,  Scott Eric Plevy MD, PhD,  Tetsuo Takehara MD, PhD,  Tetsuji Naka MD, PhD, 
  • Pages: 2169-2179
  • First Published: 28 February 2012

Basic Science Review

Free Access

What's the next best cytokine target in IBD?

Thomas T. MacDonald PhD,  Paolo Biancheri MD, PhD,  Massimiliano Sarra PhD,  Giovanni Monteleone MD, PhD, 
  • Pages: 2180-2189
  • First Published: 16 April 2012

Clinical Review

High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: Results of a meta-analysis of clinical trials†

Tessa E.H. Römkens MD,  Milou T. Kampschreur MD,  Joost P.H. Drenth MD, PhD,  Martijn G.H. van Oijen PhD,  Dirk J. de Jong MD, PhD, 
  • Pages: 2190-2198
  • First Published: 14 March 2012

Selected Summaries

Where we're going, we don't need appointments: The future of telemedicine in IBD

Seema Patil MD,  Raymond Cross MD, MS, 
  • Pages: 2199-2200
  • First Published: 17 May 2012

Stopping infliximab in crohn's disease: Still an ongoing STORI†

Laurent Peyrin-Biroulet MD, PhD,  Silvio Danese MD, PhD, 
  • Pages: 2201-2202
  • First Published: 17 May 2012